Literature DB >> 15201410

B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis.

George C Tsokos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15201410     DOI： 10.1056/NEJMp048114

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  How does B cell depletion therapy work, and how can it be improved?

Authors:  E A Clark; J A Ledbetter
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 2.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

3.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

4.  Role of sphingosine kinase and sphingosine-1-phosphate in inflammatory arthritis.

Authors:  Wen-Qi Lai; Alirio J Melendez; Bernard P Leung
Journal:  World J Biol Chem       Date:  2010-11-26

5.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 6.  B cell targeted therapies.

Authors:  Edward Keystone
Journal:  Arthritis Res Ther       Date:  2005-05-18       Impact factor: 5.156

7.  Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Authors:  Xiaomei Liu; Hui Guo; Juan Liu; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

8.  Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.

Authors:  P Bonara; G Vannucchi; I Campi; S Rossi; F Cantoni; C Frugoni; F Sbrozzi; C Guastella; S Avignone; P Beck-Peccoz; M Salvi
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Maria Chiara Sghirlanzoni; Elena Gagliardini; Sara Conti; Flavio Gaspari; Gianfranco Marchetti; Mauro Abbate; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-06       Impact factor: 8.237

10.  Targeted therapies in rheumatoid arthritis: Focus on rituximab.

Authors:  Y K Teng; T W Huizinga; J M van Laar
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.